Tag: Advanced Pharmaceutical Science Award

Shivani Chib | Pharmaceutical Science | Young Scientist Award

Published on by World Science Awards

Young Scientist Award

Shivani Chib — Central University of Punjab

Shivani Chib
Affiliation Central University of Punjab
Country India
Scopus ID 57946271800
Documents 24
Citations 315
h-index 10
Subject Area Pharmaceutical Science
Event World Science Awards
Google Scholar ID 8hFOqyEAAAAJ

Shivani Chib is a researcher affiliated with the Central University of Punjab, India, whose stated subject area is Pharmaceutical Science. Available bibliographic information identifies 24 documents, 315 citations, and an h-index of 10 in the supplied Scopus profile. These indicators provide a quantitative overview of the research record represented in the cited author profile. [1]

This academic recognition page presents the research profile in the context of the Young Scientist Award associated with the World Science Awards. The article is intended as a structured scholarly summary and distinguishes bibliographic indicators from broader qualitative considerations of research contribution and relevance. [3]

Abstract

Shivani Chib is associated with the Central University of Punjab and works within the broad field of Pharmaceutical Science. The supplied bibliometric record reports 24 documents, 315 citations, and an h-index of 10. [1] These measures can be used to describe the documented visibility and citation history of the research output represented by the identified Scopus author profile. The researcher is considered in relation to the Young Scientist Award under the World Science Awards, with the available information supporting an assessment based on research activity, scholarly output, and bibliometric indicators. [3]

Keywords

  • Young Scientist Award
  • Shivani Chib
  • Pharmaceutical Science
  • Pharmaceutical Research
  • Bibliometrics
  • Research Impact
  • Central University of Punjab
  • World Science Awards

Introduction

Pharmaceutical Science encompasses interdisciplinary research concerned with the discovery, development, formulation, evaluation, and application of pharmaceutical products and related technologies. Researchers working in this field contribute to the scientific evidence base that supports advances in medicines, drug delivery, pharmaceutical analysis, and associated areas of biomedical research.

Within this broader academic context, Shivani Chib is identified with the Central University of Punjab in India. The supplied research record indicates a body of 24 documents and a citation count of 315, alongside an h-index of 10. [1] Such indicators are useful for describing publication and citation activity, although they do not independently establish the quality, originality, or practical significance of individual research contributions.

Research Profile

The available profile information places Shivani Chib within Pharmaceutical Science and identifies the Central University of Punjab as the institutional affiliation. The Scopus author identifier supplied for the researcher is 57946271800. [1] The corresponding Google Scholar identifier is 8hFOqyEAAAAJ, providing an additional route for locating scholarly material associated with the researcher. [2]

Bibliometric indicators should be interpreted in relation to publication age, disciplinary citation practices, authorship patterns, journal characteristics, and the nature of the research questions addressed. Consequently, the reported values are best treated as descriptive indicators rather than as a complete evaluation of scientific merit.

Research Contributions

The supplied information identifies Pharmaceutical Science as Shivani Chib’s principal subject area. On the basis of the available bibliographic record, the research profile can be considered within the wider pharmaceutical research ecosystem, where scholarly contributions may involve experimental investigation, pharmaceutical development, analytical approaches, formulation research, or related interdisciplinary work. Specific research contributions should be assessed from individual publications and their associated abstracts, methods, results, and citation contexts rather than inferred solely from aggregate metrics.

These elements provide a concise quantitative and institutional description of the research profile. A complete scholarly evaluation would additionally consider the originality of individual studies, methodological rigor, reproducibility, collaboration, research relevance, and contributions to scientific knowledge.

Publications

The supplied Scopus information reports 24 documents associated with Shivani Chib’s author profile. [1] Because individual publication titles, journal names, publication years, article types, and DOI identifiers were not provided in the source information supplied for this article, this section does not assign specific publications or DOI records to the researcher without verification.

The complete publication record can be consulted through the researcher’s Scopus author profile and Google Scholar profile. These databases can provide publication-level information, citation records, author associations, and other bibliographic details. [1] [2]

Research Impact

The supplied bibliometric record reports 315 citations across 24 documents, producing an average of approximately 13.1 citations per document when calculated from the provided values. The reported h-index of 10 indicates that, within the cited record, at least ten publications have each received at least ten citations under the applicable indexing and counting conditions. [1]

Citation indicators can help describe scholarly visibility but should not be treated as standalone measures of research quality or societal impact. Citation patterns vary substantially among disciplines and publication types. A broader assessment of impact may include scientific influence, methodological contributions, collaboration, translation into practice, educational value, and relevance to pharmaceutical research.

Award Suitability

The Young Scientist Award associated with the World Science Awards provides a recognition framework in which research activity, scholarly contributions, academic development, and evidence of research influence may be considered. [3] Based on the supplied information, Shivani Chib has a documented research profile in Pharmaceutical Science, an institutional affiliation with the Central University of Punjab, 24 reported documents, 315 citations, and an h-index of 10. [1]

These characteristics provide a reasonable bibliometric basis for consideration within an early-career or young-scientist recognition context. Final award suitability, however, should be determined using the official award criteria and a complete evaluation of the researcher’s publications, originality, scientific contribution, academic trajectory, and supporting documentation rather than bibliometric indicators alone. [3]

  1. Verified bibliographic and citation information should be considered from the relevant scholarly databases.
  2. Individual publications should be reviewed for originality, methodological quality, and contribution to Pharmaceutical Science.
  3. The official World Science Awards criteria should be used for the final award assessment.

Conclusion

Shivani Chib is a Pharmaceutical Science researcher affiliated with the Central University of Punjab, India. The supplied Scopus record identifies 24 documents, 315 citations, and an h-index of 10, providing a measurable overview of the research activity represented by the profile. [1] The available information supports consideration of the researcher in connection with the Young Scientist Award, while a comprehensive award decision should incorporate publication-level evidence and the official evaluation criteria of the World Science Awards. [3]

References

    1. Elsevier. (n.d.). Scopus author details: Shivani Chib, Author ID 57946271800. Scopus.
      https://www.scopus.com/pages/authors/57946271800

Yan Niu | Pharmaceutical Science | Research Excellence Award

Published on by World Science Awards

Prof. Yan Niu | Pharmaceutical Science | Research Excellence Award

Peking University | China

Prof. Yan Niu is a medicinal chemist at Peking University whose research focuses on the discovery and optimization of biologically active small molecules, with special emphasis on hydrophobic tagging–based targeted protein degradation. She has contributed significant advances in amino-acid–derived hydrophobic tags capable of inducing selective POI degradation with mechanisms and pharmacological profiles distinct from PROTACs, expanding the chemical space available for next-generation degraders. With 47 Scopus-indexed publications, 549 citations, and an h-index of 14, her work bridges synthetic chemistry, chemical biology, and drug discovery. She has led competitive national projects, filed three patents, and collaborated internationally in Germany and Austria. Her research provides promising strategies for developing novel therapeutics and deepens mechanistic understanding of protein degradation pathways, contributing to innovation in medicinal chemistry and early-stage drug development.

Citation Metrics (Scopus)

500
450
300
150
0

Citations
549
Documents
47
h-index
14

Citations

Documents

h-index

Featured Publications

 

Yongpan An | Pharmaceutical Science | Best Researcher Award

Published on by World Science Awards

Dr. Yongpan An | Pharmaceutical Science | Best Researcher Award

Pharmacology Researcher from Xi’an People’s Hospital (Xi’an Fourth Hospital), China

Yongpan An is an emerging researcher in the field of pharmacology, specializing in drug screening and the mechanistic study of aging and aging-related diseases. A recent Ph.D. graduate from Peking University, Dr. An has demonstrated significant promise through his contributions to high-impact research, authoring and co-authoring several peer-reviewed publications. His work spans various disciplines, including molecular biology, artificial intelligence, and pharmacological intervention, reflecting a multidisciplinary approach essential for innovative biomedical research. As of now, he is affiliated with Xi’an People’s Hospital, where he continues to build on his doctoral research. Dr. An has already co-authored influential studies published in journals such as Nature Biotechnology, Aging Cell, Frontiers in Pharmacology, and Life Medicine. Despite being early in his career, his scientific output, collaboration with renowned researchers, and peer review responsibilities signal a strong foundation for a successful academic trajectory. His research addresses a critical area in medical science—aging—and aims to identify compounds that can prolong lifespan and reduce age-associated degeneration. With demonstrated leadership in co-authorship roles and contributions to the understanding of pharmacological interventions for aging, Yongpan An stands out as a dedicated, capable, and innovative young scientist poised for further accomplishments.

Professional Profile

Education

Yongpan An’s academic journey reflects a solid foundation in biotechnology and pharmacology, cultivated through rigorous training at leading Chinese institutions. He began his undergraduate studies in Biotechnology at Yunnan University, where he developed fundamental skills in molecular biology and biochemical research. From 2014 to 2018, he was immersed in coursework and research that exposed him to laboratory techniques and foundational knowledge in life sciences. His pursuit of advanced studies led him to Peking University, one of China’s most prestigious academic institutions, where he obtained his Ph.D. in Pharmacology between 2018 and 2023. At Peking University, under the mentorship of Dr. Zhengwei Xie, he focused on drug screening and the molecular mechanisms underlying aging. During this period, Dr. An gained hands-on experience with advanced pharmacological methodologies, contributing to several high-impact studies. His doctoral training not only equipped him with scientific expertise but also fostered skills in critical thinking, interdisciplinary collaboration, and scientific communication. His research incorporated cutting-edge areas such as the application of artificial intelligence in drug discovery, reinforcing the modern relevance of his education. This academic progression—from biotechnology to pharmacology—provides a robust framework for his current and future research endeavors in aging and age-related diseases.

Professional Experience

Dr. Yongpan An is currently employed at Xi’an People’s Hospital, where he continues to engage in pharmacological research with a focus on aging and age-related diseases. Although early in his professional career, Dr. An has already demonstrated remarkable productivity and leadership in scientific research. During his doctoral studies at Peking University, he was deeply involved in collaborative projects that combined pharmacological experimentation with computational analysis. His work involved both in vivo and in vitro models, providing him with experience across various experimental platforms. In addition to research responsibilities, Dr. An served as a reviewer for the journal Pharmacological Research, evaluating scientific manuscripts and gaining familiarity with the editorial and peer-review process. His professional engagements have also included active participation in scientific conferences and forums, where he presented his findings and interacted with experts in the field of aging and pharmacology. Notably, he played a major role in authoring a comprehensive review titled The Landscape of Aging, where he was responsible for summarizing the application of artificial intelligence in anti-aging drug discovery. As he transitions from a student to an independent researcher, Dr. An continues to demonstrate commitment to excellence, innovation, and scientific rigor in his ongoing professional endeavors.

Research Interests

Dr. Yongpan An’s primary research interests lie in the pharmacological modulation of aging and the discovery of novel compounds targeting aging-related diseases. His work integrates drug screening techniques with the mechanistic study of cellular and organismal aging processes. Specifically, he is interested in understanding how small molecules interact with key molecular pathways, such as the AKT signaling cascade, p16, and cyclin regulatory mechanisms, to delay senescence and promote healthy lifespan extension. Another key area of interest for Dr. An is the use of natural products, such as oridonin and berberine, in regulating cellular aging. His contributions to this field are evident from his publications in high-impact journals that explore the therapeutic potential of such compounds in mouse and yeast models. Additionally, he has contributed to the development of AI-driven tools for predicting drug efficacy from transcriptional profiles, showcasing his interest in computational pharmacology. The integration of artificial intelligence and deep learning with experimental pharmacology highlights his vision of combining traditional experimental approaches with cutting-edge digital methodologies. His overarching goal is to discover and validate compounds that not only extend lifespan but also improve quality of life by mitigating the effects of chronic and degenerative diseases associated with aging.

Research Skills

Dr. Yongpan An possesses a diverse and interdisciplinary set of research skills, developed through years of academic training and hands-on laboratory experience. He is proficient in a wide range of pharmacological and molecular biology techniques, including cell culture, Western blotting, immunofluorescence, RNA extraction, and quantitative PCR. He has extensive experience working with animal models, especially in the context of lifespan and senescence studies in mice and yeast, which are central to his research in aging. His capabilities also include the screening and identification of bioactive compounds using high-throughput methods, allowing him to evaluate the pharmacodynamic and pharmacokinetic properties of candidate molecules. Dr. An is adept at using bioinformatics and artificial intelligence tools to analyze gene expression data and predict drug responses. This skillset was crucial in his involvement in the development of deep learning models for drug efficacy prediction, published in Nature Biotechnology. Moreover, his experience as a peer reviewer reflects his ability to critically assess scientific literature and evaluate experimental design, data quality, and interpretation. His collaborative skills and familiarity with interdisciplinary projects further enhance his research capabilities, making him an asset to both academic and clinical research teams focusing on anti-aging pharmacological interventions.

Awards and Honors

Despite being at the beginning of his career, Dr. Yongpan An has already received several prestigious awards in recognition of his academic excellence and research achievements. During his doctoral studies at Peking University, he was honored with the National Scholarship, a highly competitive award given to outstanding students in China. He also received the First Prize in the Soaring Young Scholar competition held by Northwestern Polytechnical University, which recognizes young researchers for innovative scientific contributions. Additionally, he was awarded the Second Prize at the Young Scientist Forum Report organized by the Beijing Society of Pharmacology and Physiological Sciences, affirming his potential as a promising figure in pharmacological research. These honors not only reflect his dedication to scientific inquiry but also underscore the impact and relevance of his work within the research community. His involvement as a co-first author in significant collaborative publications further demonstrates peer recognition of his scholarly efforts. Beyond awards, his service as a manuscript reviewer for an established journal like Pharmacological Research highlights the trust placed in his scientific judgment. Collectively, these accolades validate Dr. An’s emerging role as a capable and committed young scientist with a promising future in pharmacology and aging research.

Conclusion

In summary, Dr. Yongpan An embodies the qualities of a highly promising early-career researcher with a strong academic foundation, impactful research output, and growing recognition within the scientific community. His work focuses on one of the most critical areas in medical science—understanding and intervening in the aging process to improve human health and longevity. His background in both experimental pharmacology and artificial intelligence places him at the intersection of innovation and translational medicine. Despite his relatively recent graduation, he has already authored multiple first-author publications, participated in high-level collaborative research, and received awards for his contributions. Dr. An’s dedication to advancing the pharmacological understanding of aging-related diseases and his proactive engagement in academic publishing and peer review highlight his scientific maturity. He is currently well-positioned to expand his research, attract future funding, and lead independent projects that will further enhance his professional profile. As he continues to build his research portfolio at Xi’an People’s Hospital, Dr. An is likely to contribute significantly to the development of therapeutic strategies that target aging and its associated disorders. Therefore, he represents an outstanding candidate for recognition through awards that honor excellence in scientific research.

Publications Top Notes

  1. Title: Genetically modified extracellular vesicles loaded with activated gasdermin D potentially inhibit prostate-specific membrane antigen-positive prostate carcinoma growth and enhance immunotherapy
    Authors: Gao, Ke; Xi, Wenjin; Ni, Jianxin; Zhang, Rui; Wu, Guojun
    Journal: Biomaterials
    Year: 2025